Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.
Clinical trial NCT06550518 · COMPLETED
Trial details
- NCT number
- NCT06550518
- Sponsor
- University Hospital, Brest
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-05-04
- Primary completion
- 2021-12-12
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.